A preclinical study in solid tumor models reported that intraperitoneal CAR-T delivery can outperform standard intravenous administration. The work in BMC Cancer found improved tumor control alongside increased CAR-T persistence in both systemic circulation and tumor tissue after regional intraperitoneal infusion. Using ⁸⁹Zr-oxine labeled CAR-T PET/CT tracking, researchers observed early tumor-associated signal within 48 hours after intraperitoneal dosing, and then confirmed trafficking and persistence advantages at endpoints using flow cytometry. The study also tested a combination with anlotinib. For developers focused on CAR-T logistics in solid tumors, the key signal is not just efficacy but distribution and persistence—two variables that often determine whether solid-tumor responses can become durable.